Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis meta-analysis

Barnabas RV, 2020
 
NCT04328961
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
407/422 safety concern
  • inconclusive 10 % increase in conversion to SARS-CoV- 2–positive status via NP swab (PE) with a high degree of certainty due to low risk of bias
  • statistically significant 58 % increase in adverse events with a high degree of certainty due to low risk of bias
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID-19 prophylaxissome concern
1116/1198 safety concern
  • inconclusive 14 % decrease in new illness compatible with Covid-19 ,symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 19.3-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
COVID PREP HCQ 1x week (Rajasingham), 2020
 
NCT04328467
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
494/494 suggested
    COVID PREP HCQ 2x week (Rajasingham), 2020
     
    NCT04328467
    RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
    495/494 safety concern
    • inconclusive 26 % decrease in new illness compatible with Covid-19 (PE) with a high degree of certainty due to low risk of bias
    • statistically significant 1.0-fold increase in adverse events with a high degree of certainty due to low risk of bias
    COVID-PEP-Post exposure (Boulware), 2020
     
    NCT04308668
    RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
    414/407 safety concern
    • statistically significant 2.3-fold increase in adverse events with a high degree of certainty due to low risk of bias
    Grau-Pujol, 2020
     
    NCT04331834
    RCThydroxychloroquineplaceboCOVID-19 prophylaxissome concern
    142/127 inconclusive
      PATCH-cohort 3 PreP (Abella), 2020
       
      NCT04329923
      RCThydroxychloroquineplaceboCOVID-19 prophylaxissome concern
      66/66 inconclusive
      • inconclusive 5 % decrease in symptomatic Covid-19,conversion to SARS-CoV- 2–positive status via NP swab (PE) with a moderate degree of certainty due to some concern in risk of bias
      2 studies excluded by filtering options (1 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).